SecBot SecBot

NEO

NEOGENOMICS INC
Nasdaq· Services-Testing Laboratories· Inc. NV· CIK 0001077183 Genomics & Gene Editing
$16.69 +0.10 (+0.60%)
Oct 26 4:00 PM ET · prev $16.59
Market cap
$2.1B
Mid cap
Consensus
Buy
69% Buy or better · 16 analysts
Median target
$20.00
+20% · range $16.50–35.00
1 year
+68.2%
from $9.92 · Oct 28
30 days
−13.5%
from $19.29
52-week range
$7.19–19.91
−16% from high · low Mar 27
Avg volume 20D
2.15M
shares / day
Short interest
14.22M
≈11.1% of shares · +0.5%
Days to cover
6.0
at average volume
Insider net
−$440.2K
0 buyers · 2 sellers · since Mar 1
New fund stakes
1
Q2 2026 13F · 0 exits
Reddit crowd
50°
Neutral · 2 mentions this week
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 1/1

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $440.2K.

  • InstitutionsBULLISH

    Q2 2026: 28 added (1 new), 8 trimmed or exited. Largest new: Arrowstreet Capital, Limited Partnership $34.9M.

  • AnalystsBULLISH

    11 of 16 rate it Buy or better. Median target $20.00 (+20%).

  • EstimatesFLAT

    Current-quarter EPS estimate $0.056 → $0.055 over 90 days. 2 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.5% to 14.22M shares. 6.0 days to cover, ≈11.1% of shares.

  • TrendDOWNTREND

    5% below its 50-day average.

  • SocialQUIET

    Crowd 50° (neutral) this week from 2 mentions: 0 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$34.9M
in new stakes
FundMoveSharesValue
FIRST TRUST ADVISORS LPADD10,113,261$147.6M
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.ADD5,037,787$73.5M
MILLENNIUM MANAGEMENT LLCADD3,079,542$44.9M
LOOMIS SAYLES & CO L PADD2,537,717$37.0M
DRIEHAUS CAPITAL MANAGEMENT LLCADD2,508,845$36.6M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPNEW2,391,784$34.9M
D. E. Shaw & Co., Inc.TRIM2,194,758$32.0M
GOLDMAN SACHS GROUP INCADD1,566,760$22.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 69% rate it Buy or better
Strong Buy4Buy7Hold5Sell0Strong Sell0
12-month targets · 10 analysts

Price is inside the target range. Median implies +20%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Oct 6, 2026StoneX
MAINTAIN
MAINTAINBuy
Oct 6, 2026Needham
MAINTAIN
MAINTAINBuy
Oct 6, 2026BTIG
UPGRADE
UPGRADEBuy
Jul 29, 2026Needham
MAINTAIN
MAINTAINBuy
Jul 24, 2026Benchmark
MAINTAIN
MAINTAINBuy
Congressional trades
NEO trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 0 sells
DateMemberType AmountDisclosed
Aug 7, 2026 Gilbert CisnerosDHouse Neogenomics Inc BUY $1K–$15K Sep 10, 2026 +34d

Insider ledger

Form 4
$0
bought · 0 insiders
$440.2K
sold · 2 insiders
DateInsiderTypeValue
Oct 1, 2026
Stone Warren
Pres & Chief Operating Officer
EXERCISE17,562 sh
Oct 1, 2026
Stone Warren
Pres & Chief Operating Officer
TAX W/H6,911 sh
Sep 1, 2026
Olivo Alicia C
EVP, GC & Business Development
TAX W/H2,692 sh
Aug 21, 2026
Stone Warren
Pres & Chief Operating Officer
EXERCISE28,106 sh
Aug 21, 2026
Stone Warren
Pres & Chief Operating Officer
TAX W/H11,060 sh
Aug 4, 2026
Aunan Greg D
Chief Accounting Officer
SELL$321.4K
Jun 23, 2026
Starrett Carolyn S
Director
AWARD14,125 sh
Jun 23, 2026
Starrett Carolyn S
Director
AWARD9,784 sh

Earnings setup

Estimates
$0.06
EPS estimate, this quarter
−1%
estimate change, 90 days
2↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.06$0.04–$0.07+3.4%$207.3M
Next Q$0.07$0.06–$0.08+1.3%$210.2M
Current FY$0.19$0.16–$0.20+2.5%$805.6M
Next FY🔒 Fresh data, subscribers only
Reddit mentions per day, 14 days
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 2 0 in posts · 2 in comments
Recent comments
All social signals and their track records

Short side

FINRA· Oct 15, 2026
14,215,304
shares short
+0.5%
vs prior settlement
6.0
days to cover
≈11.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 28, 2026 Earnings calendar
🔒 Fresh data, subscribers only
Oct 5, 2026 SEC
NeoGenomics announced a planned CEO succession: President/COO Warren Stone will become CEO effective Jan 4, 2027…
8-K — Impact 5/10
Oct 1, 2026 Insider
Stone Warren acquired via exercise 17,562 shares
Pres & Chief Operating Officer
Oct 1, 2026 Insider
Stone Warren surrendered for taxes 6,911 shares
Pres & Chief Operating Officer
Sep 1, 2026 Insider
Olivo Alicia C surrendered for taxes 2,692 shares
EVP, GC & Business Development
Aug 7, 2026 Congress
Gilbert Cisneros buy
$1,001 - $15,000 — House
Jul 20, 2026 SEC
NeoGenomics finalized a civil settlement with the DOJ for $9.8M, resolving a legacy investigation into consulting…
8-K — Impact 4/10
Jun 30, 2026 Inst.
FIRST TRUST ADVISORS LP — ADD
10,113,261 shares ($147.6M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 28, 2026
Earnings date
🔒 Fresh data, subscribers only
Jul 28, 2026
Earnings date
NEO Q2 2026 Earnings Before Market Open — 2026-07-28
Jun 30, 2026
Short interest
Short Interest: NEO up 37% to 11.6M shares
Settlement 2026-06-30 | Days to cover: 2.11 | ≈8.92% of shares outstanding (est.)
Apr 28, 2026
Earnings date
NEO Q1 2026 Earnings Before Market Open — 2026-04-28
Mar 3, 2026
Short interest
FTD: NEO — 54,551 shares ($0.5M) failed to deliver
Settlement: 20260303, Price: $9.50, FTD Value: $518,234.5, NEOGENOMICS INC NEW

SecBot reports

4 filings · 1 bullish · 0 bearish · 1 mixed · 2 neutral
All NEO filing & press-release reports (4)